Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Rheumatoid Arthritis
About this trial
This is an interventional treatment trial for Rheumatoid Arthritis focused on measuring Rheumatoid Arthritis, Monoclonal Antibody, Interleukin-6, Olokizumab, CDP6038
Eligibility Criteria
Inclusion Criteria:
- Have a diagnosis of adult-onset RA of at least 6 months' (24 weeks) duration as defined by the 1987 ACR classification criteria or a score of ≥6 as defined by the ACR/European League Against Rheumatism Classification and Diagnostic Criteria for RA
- Must have moderately to severely active RA disease as defined by ≥6 tender joints (68-joint count) at Screening and Baseline, ≥6 swollen joints (66-joint count) at Screening and Baseline, CRP ≥1.2 times the upper limit of normal (ULN) or ESR >28mm/hour
- Must be on an MTX dose of 6 to 16mg/week in Japan or 7.5 to 20mg/week in Korea and Taiwan, which has been stable for at least 6 weeks prior to Screening with a stable route of administration
- Must have had intolerance or inadequate response to treatment with 1 or more TNF-blocker therapies within 2 years of Screening
- Female subjects must be either postmenopausal for at least 1 year, surgically incapable of childbearing, or effectively practicing 2 acceptable methods of contraception
Exclusion Criteria:
- Have a diagnosis of any other inflammatory arthritis
- Female subjects who are breast-feeding, pregnant, or plan to become pregnant during the study or within 24 weeks
- Disease modifying antirheumatic drug (DMARDs) other than methotrexate (MTX)
- Subjects with known concurrent acute or chronic viral hepatitis B or C infection
- Subject has known tuberculosis (TB) disease, high risk of acquiring TB infection, or latent TB infection
- Subjects with known history of or current clinically active infection
- Subjects at high risk of infection
- Subjects with known human immunodeficiency virus (HIV) or human T cell lymphotropic virus type 1 (HTLV 1) infection
- Have received vaccinations within 8 weeks prior to Screening or plan to receive vaccines during the study (with the exception of injectable influenza and pneumococcal vaccinations which are permitted)
- Concurrent malignancy or a history of malignancy (with the exception of successfully treated carcinoma of the cervix more than 5 years prior to Screening or no more than 2 successfully treated basal cell carcinomas within 2 years prior to Screening
Sites / Locations
- 102
- 114
- 115
- 113
- 120
- 118
- 116
- 121
- 122
- 107
- 110
- 103
- 119
- 112
- 100
- 117
- 124
- 123
- 101
- 108
- 111
- 105
- 104
- 200
- 201
- 202
- 203
- 204
- 303
- 304
- 305
- 300
- 301
- 306
- 307
- 302
- 308
- 309
- 310
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Placebo Comparator
Experimental
Experimental
Experimental
Experimental
Experimental
Placebo every 2 weeks
Olokizumab 60 mg every 2 weeks
Olokizumab 60 mg every 4 weeks
Olokizumab 120 mg every 2 weeks
Olokizumab 120 mg every 4 weeks
Olokizumab 240 mg very 4 weeks
Injections administered at week 0, 2, 4, 6, 8 and 10
Olokizumab 60 mg injections administered at week 0, 2, 4, 6, 8 and 10
Olokizumab 60 mg injection administered at week 0, 4, and 8 and Placebo injection administered at week 2, 6, and 10
Olokizumab 120 mg injections administered at week 0, 2, 4, 6, 8 and 10
Olokizumab 120 mg injections administered at week 0, 4 and 8 and Placebo injections at week 2, 6 and 10
Olokizumab 240 mg injections administered at week 0, 4 and 8 and Placebo injections at week 2, 6 and 10